TELA Bio — Third Quarter 2026 Earnings Summary

TELA Bio reported third-quarter 2026 revenue of $19.0 million, representing an 8% decline from the prior year period, driven by lower OviTex PRS volumes despite an 18% increase in international sales. The company reduced its sequential operating loss by 21% to $7.3 million and decreased its adjusted EBITDA loss by 55% to $3.4 million, aided by a strategic cost reduction initiative targeting $17.0 million in annual expense cuts. On a GAAP basis, the net loss for the quarter was $9.3 million, or $0.16 per share, while cash and cash equivalents stood at $22.7 million as of September 30, 2026. Additionally, TELA Bio regained compliance with Nasdaq's minimum bid price requirement and received 510(k) clearance for its Liora Monofilament Scaffold.